ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

NCT07157969 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

300

Enrollment

OTHER

Sponsor class

Conditions

HCC - Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib
DRUG: Pembrolizumab
DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: Camrelizumab
DRUG: Apatinib
PROCEDURE: TACE
PROCEDURE: HAIC
PROCEDURE: DEB-TACE
DRUG: Tislelizumab
DRUG: Sintilimab

Sponsor

Peking Union Medical College Hospital